Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients With Stable CAD
| Autor: | Breno de Alencar Araripe Falcão, Expedito E. Ribeiro, Bruno Moulin, Gustavo R. Morais, Rutao Wang, Masafumi Ono, Hironori Hara, Pedro A. Lemos, Fernanda Barbosa de Almeida Sampaio, Rodrigo Modolo, Norihiro Kogame, João Eduardo Prudêncio Tinoco, Hideyuki Kawashima, Yoshinobu Onuma, Fernando de Martino, George C. Meireles, Rafael Cavalcante, Carlos M. Campos, Patrícia O. Guimarães, Rogério S. Leite, Patrick W. Serruys |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Aspirin Prasugrel business.industry medicine.medical_treatment Percutaneous coronary intervention 030204 cardiovascular system & hematology medicine.disease Cardiac surgery Surgery Coronary artery disease 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure Conventional PCI medicine In patient cardiovascular diseases 030212 general & internal medicine Cardiology and Cardiovascular Medicine business Artery medicine.drug |
| Zdroj: | JACC: Cardiovascular Interventions. 13:2251-2262 |
| ISSN: | 1936-8798 |
| DOI: | 10.1016/j.jcin.2020.06.023 |
| Popis: | Objectives The aim of this study was to evaluate the hypothesis that prasugrel monotherapy following successful everolimus-eluting stent implantation is feasible and safe in patients with stable coronary artery disease (CAD). Background Recent studies have suggested that short dual-antiplatelet therapy strategies may provide an adequate balance between ischemic and bleeding risks. However, the complete omission of aspirin immediately after percutaneous coronary intervention (PCI) has not been tested so far. Methods The study was a multicenter, single-arm, open-label trial with a stopping rule based on the occurrence of definite stent thrombosis (if >3, trial enrollment would be terminated). Patients undergoing successful everolimus-eluting stent implantation for stable CAD with SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) scores Results From February 22, 2018, to May 7, 2019, 201 patients were enrolled. All patients underwent PCI for stable CAD. Overall, 98.5% of patients were adherent to prasugrel at 3-month follow-up. The primary ischemic and bleeding endpoints occurred in 1 patient (0.5%). No stent thrombosis events occurred. Conclusions Aspirin-free prasugrel monotherapy following successful everolimus-eluting stent implantation demonstrated feasibility and safety without any stent thrombosis in selected low-risk patients with stable CAD. These findings may help underpin larger randomized controlled studies to evaluate the aspirin-free strategy compared with traditional dual-antiplatelet therapy following PCI. (Acetyl Salicylic Elimination Trial: The ASET Pilot Study [ASET]; NCT03469856) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|